Shares of Replimune Group, Inc. (NASDAQ: NASDAQ: REPL) surged 17% following the announcement that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for ...

PDUFA action date of July 22, 2025, with priority reviewWOBURN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the ...

The biologics license application for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma was accepted by the ...

Childhood cancer survivors had greater than twofold increased risk of invasive skin and ocular melanoma (95% CI 1.6-2.4) ...

(RTTNews) - Replimune Group, Inc. (REPL), Tuesday announced that the U.S. Food and Drug Administration has accepted the Biologics License Application for RP1 in combination with Nivolumab for the ...

A topical treatment combining calcipotriol and 5-FU shows promise in reducing premalignant lesions and lowering skin cancer ...

Evaxion Biotech has completed subject dosing in the Phase II trial of EVX-01, for the treatment of advanced melanoma.

Cancers of the eye are exceedingly rare, and only a rare handful of cancer clinics in the nation are equipped to deal with ...

Molecular oncology is revolutionizing cancer care by using genetic profiling to tailor personalized treatments, improving ...

Moles appear commonly on human skin, yet their presence demands attention and regular monitoring. While most remain harmless, ...

Latine individuals in the US face higher morbidity and mortality in skin cancer outcomes despite lower lifetime risk.

A phase 2a trial of IMM-1-104 plus chemotherapy demonstrated efficacy and tolerability in first- and second-line pancreatic ...